NEW ORLEANS, LA—Ticagrelor did not prove to be noninferior to prasugrel as part of dual antiplatelet therapy (DAPT) following PCI in patients with diabetes and multivessel coronary disease in the ...
When choosing a P2Y12 inhibitor to use in combination with aspirin in patients with diabetes undergoing percutaneous coronary intervention (PCI) for multivessel disease, prasugrel may be preferable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results